NO923126L - Preparat og metode for behandling av canser - Google Patents

Preparat og metode for behandling av canser

Info

Publication number
NO923126L
NO923126L NO92923126A NO923126A NO923126L NO 923126 L NO923126 L NO 923126L NO 92923126 A NO92923126 A NO 92923126A NO 923126 A NO923126 A NO 923126A NO 923126 L NO923126 L NO 923126L
Authority
NO
Norway
Prior art keywords
different
same
group
chem
alkyl group
Prior art date
Application number
NO92923126A
Other languages
English (en)
Norwegian (no)
Other versions
NO923126D0 (no
Inventor
Lan Bo Chen
Tadao Shishido
Original Assignee
Fuji Photo Film Co Ltd
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Photo Film Co Ltd, Dana Farber Cancer Inst Inc filed Critical Fuji Photo Film Co Ltd
Publication of NO923126D0 publication Critical patent/NO923126D0/no
Publication of NO923126L publication Critical patent/NO923126L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gas Separation By Absorption (AREA)
  • Luminescent Compositions (AREA)
  • Paper (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
NO92923126A 1991-08-13 1992-08-11 Preparat og metode for behandling av canser NO923126L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74413091A 1991-08-13 1991-08-13

Publications (2)

Publication Number Publication Date
NO923126D0 NO923126D0 (no) 1992-08-11
NO923126L true NO923126L (no) 1993-02-15

Family

ID=24991548

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92923126A NO923126L (no) 1991-08-13 1992-08-11 Preparat og metode for behandling av canser

Country Status (15)

Country Link
US (1) US5360803A (hu)
EP (1) EP0527494B1 (hu)
JP (1) JP2567328B2 (hu)
CN (1) CN1071834A (hu)
AT (1) ATE144897T1 (hu)
AU (1) AU649865B2 (hu)
CA (1) CA2075750C (hu)
DE (1) DE69215035T2 (hu)
DK (1) DK0527494T3 (hu)
ES (1) ES2096685T3 (hu)
FI (1) FI923604A (hu)
GR (1) GR3021865T3 (hu)
HU (1) HUT64224A (hu)
NO (1) NO923126L (hu)
ZA (1) ZA926004B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599825A (en) * 1994-07-21 1997-02-04 Fuji Photo Film Co., Ltd. Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same
WO1996003393A1 (en) * 1994-07-21 1996-02-08 Fuji Photo Film Co., Ltd. Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same
JPH0921985A (ja) * 1995-07-07 1997-01-21 Nec Corp マッハツェンダー変調器及びその製造方法
DE69630639T2 (de) 1995-08-16 2004-09-16 Huntington Medical Research Institutes, Pasadena Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs
US7329741B2 (en) * 1996-06-05 2008-02-12 Chiron Corporation Polynucleotides that hybridize to DP-75 and their use
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10032290C2 (de) * 2000-07-03 2002-05-08 Roche Diagnostics Gmbh Adsorptionsmittelhaltige Kontrollflüssigkeit
JP2003034641A (ja) * 2001-07-19 2003-02-07 Japan Science & Technology Corp ロダシアニン系色素化合物を含有する抗マラリア剤
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
JP2004331545A (ja) * 2003-05-06 2004-11-25 Japan Science & Technology Agency 抗リーシュマニア剤
FR2874319B1 (fr) * 2004-08-19 2008-05-16 Oreal Composition pour la teinture des fibres keratiniques comprenant un colorant direct methinique contenant un motif benzoselenazolium
JP4553355B2 (ja) 2004-10-04 2010-09-29 富士フイルム株式会社 トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物
US20060099712A1 (en) * 2004-11-08 2006-05-11 Eastman Kodak Company Correlation of anti-cancer activity of dyes with redox potentials
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
GB0603455D0 (en) * 2006-02-21 2006-04-05 Cancer Rec Tech Ltd Therapeutic compounds
JP2010505750A (ja) * 2006-09-14 2010-02-25 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 腫瘍疾患治療のための混合治療
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
US9642843B2 (en) * 2013-02-27 2017-05-09 The Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
CN104177312B (zh) * 2013-05-27 2018-02-13 黄英武 一种含硒化合物及其医药用途
EP3242555A4 (en) 2015-01-09 2018-06-27 The Regents of The University of California Oxathiazole thiazolium hsp 70 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2536986A (en) * 1951-01-02 Thiazolone cyan
GB487051A (en) * 1936-11-14 1938-06-14 John David Kendall Improvements in or relating to dyestuffs
GB489335A (en) * 1937-01-22 1938-07-22 Douglas James Fry Improvements in or relating to the manufacture and use of dyestuffs suitable for sensitising photographic emulsions
US2454629A (en) * 1940-01-27 1948-11-23 Eastman Kodak Co Polymethine dyes
BE485785A (hu) * 1947-11-18
BE571507A (hu) * 1957-09-30
US3454629A (en) * 1962-08-17 1969-07-08 Ciba Geigy Corp Novel phenylalanine compounds
JPS53144727A (en) * 1977-05-24 1978-12-16 Konishiroku Photo Ind Co Ltd Photographic product
JPS54151133A (en) * 1978-05-17 1979-11-28 Takeda Chem Ind Ltd Antitumorigenic agent
JPS5569513A (en) * 1978-11-20 1980-05-26 Takeda Chem Ind Ltd Anti-tumor agent
DE2919447A1 (de) * 1978-05-17 1979-11-22 Takeda Chemical Industries Ltd Tumorhemmendes mittel
JPS55100318A (en) * 1979-01-26 1980-07-31 Takeda Chem Ind Ltd Antitumorigenic agent
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
JPH0652210B2 (ja) * 1987-08-26 1994-07-06 宣行 杉村 アキユムレ−タのガス封入圧力測定方法
JP2824917B2 (ja) * 1989-08-30 1998-11-18 株式会社林原生物化学研究所 抗腫瘍剤

Also Published As

Publication number Publication date
JPH06172330A (ja) 1994-06-21
CA2075750C (en) 1998-02-24
EP0527494A1 (en) 1993-02-17
AU649865B2 (en) 1994-06-02
DK0527494T3 (da) 1996-11-25
US5360803A (en) 1994-11-01
FI923604A (fi) 1993-02-14
FI923604A0 (fi) 1992-08-12
GR3021865T3 (en) 1997-03-31
NO923126D0 (no) 1992-08-11
ATE144897T1 (de) 1996-11-15
CN1071834A (zh) 1993-05-12
CA2075750A1 (en) 1993-02-14
ZA926004B (en) 1993-03-02
HUT64224A (en) 1993-12-28
JP2567328B2 (ja) 1996-12-25
ES2096685T3 (es) 1997-03-16
AU2097492A (en) 1993-02-25
DE69215035T2 (de) 1997-04-03
HU9202609D0 (en) 1992-10-28
EP0527494B1 (en) 1996-11-06
DE69215035D1 (de) 1996-12-12

Similar Documents

Publication Publication Date Title
NO923126D0 (no) Preparat og metode for behandling av canser
DE122008000051I1 (de) 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
DE69232336D1 (de) Stickstoff enthaltende hydrocyclische verbindungen
EP0767170A4 (en) 4,6-DIARYLPYRIMIDINE DERIVATIVES AND THEIR SALTS
IE802612L (en) Bicyclo £2.2.1| heptane derivatives
NO306992B1 (no) Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
HUT68721A (en) Benzofuran and benzizoxazole derivatives, pharmaceutical composition containing said compounds as active agent and process for preparing them
RU94002335A (ru) Производные хинолина или хиназолина и способ их получения
JO1617B1 (en) Modern 2-amino-tetraline-8 compounds
ES8307792A1 (es) Un metodo de produccion de compuesto de dihidropiridina.
ATE32894T1 (de) Thiomethylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
PT87025A (pt) Process for the preparation of imidazol derivatives and of pharmaceutical compositions containing the same
DE69201848D1 (de) Verfahren zum Härten von Gelatine.
DK360388D0 (da) Laegemiddel til behandling af hjerteinsufficiens
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
TH8849EX (th) 8-ซับสทิทิวเทด-2-อะมิโนเททระลีนชนิดใหม่
BE900322A (fr) Nouveaux derives du 1,2,4-triazole.